7 Best Peptides for Anemia

What to Know Before Choosing a Peptide for Anemia

Anemia is not one condition. It is a broad category that includes iron deficiency, the anemia driven by chronic inflammation, the reduced red blood cell production that comes with kidney disease, and several genetic blood disorders that each disrupt erythropoiesis in different ways. That matters for this guide because the peptides people use for anemia are not interchangeable. Some target iron regulation. Some support the bone marrow directly. Some work by dialing back the inflammatory signals that block iron from being used. The right question is not just "which peptide" but "which peptide for which mechanism."

Every compound in this list earned its slot because people use it for anemia support, or are actively discussing using it. That is the whole test. FDA approval is not the filter, clinical trial depth is not the filter, and regulatory status in any particular country is not the filter. A compound used in Russian clinical practice with limited Western peer-reviewed data belongs here just as much as a synthetic peptide in Phase 1 trials in the United States. What differs between them is how the evidence is described, not whether they appear. Where human trial data exists, that is stated plainly. Where the evidence is animal-model only or comes from community and practitioner use, that is stated just as plainly.

The entries that follow are numbered by how prominently each compound appears in the research and in real-world use, not as a ranking of one being better than another for your situation. A compound listed later is not a lesser option; it may simply be relevant to a narrower or more specific type of anemia. One caveat worth stating once: the peptide-based anemia landscape is largely preclinical or early clinical as of 2026. No compound in this list is FDA-approved with anemia as its primary indication. Read each entry on its own terms.

1. Bonomarlot: For Bone Marrow Hematopoietic Support

Bonomarlot is a peptide bioregulator derived from bone marrow tissue, developed through decades of research at the Institute of Bioregulation and Gerontology in St. Petersburg, Russia. It belongs to a class of compounds called cytamines, which are short-chain peptide complexes extracted from specific animal organs and theorized to restore functional activity to the corresponding organ type in a recipient. In Bonomarlot's case, the source is bone marrow, and the target is hematopoietic tissue, the network of cells in the marrow responsible for producing red blood cells, white blood cells, and platelets.

The proposed mechanism works at the level of bone marrow stem cells and precursor cells. Organ-specific short peptides are thought to interact with these cells through cell-signaling or epigenetic pathways, normalizing the marrow's output when that output has been suppressed or dysregulated, whether by aging, chronic illness, chemotherapy, or other causes. For anemia specifically, the theory holds that restoring bone marrow regulatory homeostasis increases red blood cell production at the source. This makes Bonomarlot most relevant to anemias rooted in bone marrow suppression or age-related decline in hematopoiesis rather than to iron deficiency or the inflammation-driven variety.

The evidence base for Bonomarlot is real but limited by Western standards. Research has been published through the Russian bioregulator program, including human studies, though much of it appears in Russian-language literature with limited availability in major Western journals. No randomized controlled trial specifically evaluating Bonomarlot against hemoglobin or red blood cell count endpoints has been published in PubMed or ClinicalTrials.gov as of 2026. What exists is practitioner use in Russia and some post-Soviet states, where it is available as an oral supplement, general cytamine bioregulator data on longevity and organ function, and a body of theory grounded in the cytamine hypothesis rather than in head-to-head clinical trial data. People who use Bonomarlot for anemia are working within that Russian bioregulator framework, and the honest characterization is that the evidence is supportive in principle but not yet validated by Western clinical trial standards for anemia endpoints. It is available through international peptide and supplement suppliers as a research compound and is not FDA-approved or available by prescription in the United States or European Union.

2. Thymalin: For the Inflammatory Driver of Anemia

Thymalin is a thymus-derived peptide bioregulator from the same Russian research program that produced Bonomarlot. Where Bonomarlot targets bone marrow directly, Thymalin's primary domain is immunomodulation. It is composed of short peptides including thymulin-related sequences extracted from thymus gland tissue, and its core action involves normalizing T-cell development and broader immune function, particularly in aging populations where thymic activity has declined.

The connection to anemia runs through the inflammatory pathway. Anemia of chronic disease, one of the most common forms of anemia worldwide, is driven by chronic inflammation. Inflammatory signaling molecules, particularly interleukin-6, trigger the liver to overproduce hepcidin, the hormone that controls iron release from storage cells. When hepcidin is chronically elevated, iron stays trapped in macrophages and liver cells, and the bone marrow cannot access enough of it to produce adequate hemoglobin. By reducing the inflammatory environment that drives this cycle, Thymalin could theoretically lower hepcidin levels and free up iron for red blood cell synthesis. The effect is indirect but mechanistically grounded: address the immune dysregulation that feeds the anemia rather than treating the red blood cell deficit directly.

The evidence for Thymalin in human longevity and immune function is stronger than its evidence specifically for anemia. A long-term study followed elderly patients treated with Thymalin over several years and reported improvements in immune parameters and reductions in mortality, though anemia was not the primary endpoint measured. No dedicated human trial for anemia outcomes has been published in Western peer-reviewed literature as of 2026. The connection between Thymalin's immunomodulatory effects and anemia of chronic disease rests on what research shows about the hepcidin-inflammation axis rather than on a trial that measured hemoglobin before and after Thymalin treatment. Practitioners who use it for anemia in the context of chronic disease or aging are drawing on that mechanistic logic and on the broader Russian bioregulator literature. Like Bonomarlot, it is available as an oral supplement through international suppliers, is not FDA-approved, and carries no established anemia-specific clinical data by Western standards.

3. Minihepcidins: For Iron-Overload Anemias

Minihepcidins are synthetic peptides engineered to mimic hepcidin, the liver-produced hormone that serves as the master regulator of iron in the body. The lead compound in clinical development is M012, developed by Merganser Biotech. Unlike the other compounds on this list, minihepcidins are not available outside of clinical trials, but they are generating real discussion in the hematology community as a potential treatment for a specific and difficult-to-treat category of anemia.

To understand why minihepcidins are relevant to anemia at all, it helps to understand what hepcidin actually does. Hepcidin binds to ferroportin, which is the sole transporter that moves iron out of storage cells and into circulation. When hepcidin binds ferroportin, it triggers that transporter's degradation, locking iron inside cells and dropping circulating iron levels. In healthy physiology this is a regulatory mechanism. In conditions like beta-thalassemia and polycythemia vera, the problem is the opposite: too much iron circulates and accumulates, damaging red blood cell precursors and making erythropoiesis ineffective. By mimicking hepcidin and pushing ferroportin off the cell surface, minihepcidins restrict iron absorption and release, normalizing the erythropoietic environment.

This mechanism is worth stating clearly because it is counterintuitive. Minihepcidins do not treat iron deficiency anemia and would worsen it. They are designed for iron-overload anemias where excess iron is disrupting blood cell production, not insufficient iron. In mouse models of beta-thalassemia, minihepcidin treatment restored normal red blood cell levels and reduced spleen enlargement caused by the body's attempt to compensate for ineffective erythropoiesis. M012 has entered Phase 1 clinical trials to evaluate safety in humans, and no efficacy data from human trials has been published as of 2026. Researchers working on this compound have been explicit that preclinical results are promising but translation to humans remains to be established. This is early-stage clinical research, not an available treatment, but it represents one of the most mechanistically novel peptide approaches in the anemia space.

4. Hepcidin-Binding Peptide: For Anemia of Chronic Disease

Where minihepcidins mimic hepcidin to restrict iron in overload conditions, hepcidin-binding peptides work in the opposite direction. They are synthetic peptides designed to bind and neutralize endogenous hepcidin, and they are being investigated for anemia of chronic disease, the form of anemia where excess hepcidin is the central problem.

In anemia of chronic disease, chronic inflammation causes the liver to continuously produce high levels of hepcidin. That excess hepcidin blocks ferroportin on macrophages and storage cells, trapping iron the body actually has in adequate supply. The bone marrow cannot get to it. A hepcidin-binding peptide intercepts free hepcidin before it reaches ferroportin, neutralizing it and allowing iron to flow normally from storage into circulation and then into red blood cell production. This approach does not increase iron absorption from the gut. It frees iron that is already in the body but functionally unavailable because of inflammatory signaling.

Research published in Blood has provided preclinical evidence that hepcidin-binding peptides can ameliorate anemia of chronic disease in animal models, demonstrating the concept at the mechanistic level. No human trial data for hepcidin-binding peptides has been published as of 2026. This remains a preclinical research area, and no compound of this type is available outside of research settings. It earns a place in this guide because the mechanistic case for it in anemia of chronic disease is among the most direct of any peptide approach here, and it is being actively discussed in the hematology research community as a direction worth pursuing.

5. Iron-Chelating Food-Derived Peptides: For Iron Deficiency Anemia

A different category of anemia-relevant peptides has been attracting research attention for iron deficiency anemia specifically. This category involves short peptides derived from food sources that are chelated with ferrous iron to improve how the body absorbs it. The two most studied examples are a pig skin collagen peptide ferrous chelate and an Antarctic krill peptide iron complex.

The core idea is that peptide functional groups, meaning the amino acids in a short peptide chain, can bind ferrous iron into a stable chelate that protects it from oxidation in the gastrointestinal tract and delivers it more efficiently to intestinal absorptive cells. Standard iron supplements like ferrous sulfate release free ionic iron in the gut, which causes irritation and is partially lost to oxidation before absorption. A peptide chelate keeps the iron bound and bioavailable longer. Research in rat models of iron deficiency anemia found that the pig skin collagen peptide chelate reversed anemia markers including hemoglobin, red blood cell counts, and serum iron more effectively than standard ferrous sulfate, and showed lower liver toxicity in the process. A separate mouse study found similar results with the krill peptide iron complex, again outperforming ferrous sulfate on hemoglobin and iron store restoration.

Both of these peptide systems have been studied in animals only as of 2026. No human clinical trial data has been published for either. They are being developed as functional food ingredients or specialty supplement components rather than as prescription drugs, and neither is available as a standalone commercial product yet. The research is early but directionally consistent: multiple independent animal studies across different peptide sources have shown the chelation approach outperforms standard iron supplementation on key anemia endpoints. This category earns its place here because people researching novel approaches to iron deficiency anemia are actively discussing it in nutritional science and functional medicine contexts.

6. Sotatercept: For Ineffective Erythropoiesis

Sotatercept is a fusion protein that traps a signaling molecule called GDF11, a member of the bone morphogenetic protein family. GDF11 normally acts as a brake on the late stages of erythropoiesis, suppressing the maturation of red blood cell precursors. By sequestering GDF11 and removing that brake, sotatercept stimulates the maturation step that converts precursor cells into functional red blood cells. This mechanism is distinct from erythropoietin-based therapies, which act earlier in the process by stimulating the proliferation of red blood cell precursors rather than their maturation.

Sotatercept received FDA approval in 2024 under the name Winrevair, but that approval is for pulmonary arterial hypertension, not anemia. Its relevance to anemia comes from investigational trials in beta-thalassemia and myelodysplastic syndrome, where ineffective erythropoiesis, the failure of precursor cells to complete their maturation into red blood cells, is a central driver of the condition. In these trials, sotatercept has shown the ability to support erythroid maturation, and clinical research in these hematological indications is ongoing as of 2026. The anemia indication remains investigational, meaning it is explored through clinical trials and off-label investigation rather than as an approved anemia therapy.

Sotatercept is a large fusion protein that requires physician prescription and clinical administration, not a research peptide that circulates in community protocols. It belongs in this guide because it represents the most clinically advanced peptide-adjacent erythropoiesis-modulating compound being actively investigated for anemia, and people researching anemia in the context of thalassemia or myelodysplastic conditions will encounter it in the literature.

7. Peginesatide: The Historical Synthetic EpoR Peptide

Peginesatide occupies a unique position in the history of peptide-based anemia treatment. It is the only synthetic peptide that successfully activated the erythropoietin receptor in humans using an amino acid sequence completely unrelated to natural erythropoietin. This distinction matters scientifically because it proved the erythropoietin receptor could be activated by a non-EPO molecule, opening a conceptual door for future peptide design.

The compound was developed for a specific and difficult clinical problem: pure red cell aplasia caused by anti-erythropoietin antibodies. In this condition, the immune system generates antibodies against endogenous erythropoietin and against standard erythropoietin-based drugs, rendering conventional anemia therapy ineffective. Because peginesatide's amino acid sequence bore no resemblance to erythropoietin, those antibodies did not recognize it. A clinical study published in the New England Journal of Medicine found that peginesatide corrected anemia in 13 of 14 patients with this condition, raising hemoglobin above 11 grams per deciliter where standard treatment had failed entirely.

Peginesatide was briefly marketed under the name Omontys before being voluntarily withdrawn in February 2013 following reports of severe anaphylaxis. All cases occurred within 30 minutes of the first intravenous dose, and a fatal anaphylaxis rate was identified that made the risk profile unacceptable for routine clinical use. It is no longer available. It is included here because it remains a reference point in peptide-based anemia research and continues to be discussed in the scientific community for what it demonstrated, and ultimately revealed, about synthetic erythropoietin receptor agonist peptides.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved specifically for anemia?

No peptide on this list is currently FDA-approved with anemia as its primary indication. Sotatercept holds FDA approval for pulmonary arterial hypertension and is being investigated for anemia in separate clinical trials. Erythropoiesis-stimulating agents like epoetin alfa are FDA-approved for anemia in specific contexts but are large glycoprotein biologics rather than small peptides. The peptide-based anemia landscape is largely preclinical or early clinical as of 2026.

Can peptides help with iron deficiency anemia specifically?

The iron-chelating food-derived peptides, including pig skin collagen peptide chelates and krill peptide iron complexes, are being studied for exactly this type of anemia. They work by binding ferrous iron in a form that is more bioavailable and easier on the gastrointestinal tract than standard iron supplements. As of 2026, the evidence is from animal models only, with no published human trial data. They are not available as standalone commercial products and remain in the research and development stage.

What is the difference between minihepcidins and hepcidin-binding peptides?

They work in opposite directions, and the distinction matters for which type of anemia they address. Minihepcidins mimic hepcidin, pushing ferroportin off cells to restrict iron movement, which is useful in iron-overload conditions like beta-thalassemia. Hepcidin-binding peptides neutralize hepcidin, freeing up ferroportin so iron can move out of storage, which is the approach relevant to anemia of chronic disease where excess hepcidin is trapping iron the body already has. Using the wrong approach for the wrong anemia type would be counterproductive.

How do Bonomarlot and Thymalin differ from other anemia peptides?

Bonomarlot and Thymalin are peptide bioregulators developed within the Russian cytamine research framework, and they differ from the other compounds on this list in several notable ways. Both are available as oral supplements rather than injectables, both operate through indirect systemic mechanisms rather than directly stimulating erythropoiesis, and both derive their evidence base primarily from Russian-language literature and practitioner use rather than from Western randomized controlled trials. Bonomarlot targets bone marrow function directly while Thymalin works through immune normalization. Neither has dedicated anemia endpoint data from Western peer-reviewed clinical trials as of 2026.

Is peginesatide still available or being redeveloped?

Peginesatide was voluntarily withdrawn in February 2013 after cases of severe anaphylaxis were identified, and it is not currently available. Whether the compound or a chemically modified successor will be redeveloped is not established in the public literature as of 2026. It remains a reference point in the history of synthetic erythropoietin receptor agonist research and is discussed in the scientific community for what it demonstrated about non-EPO peptide activation of that receptor.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for anemia in one place.